| Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling F Hakim, Y Wang, SXL Zhang, J Zheng, ES Yolcu, A Carreras, A Khalyfa, ... Cancer research 74 (5), 1329-1337, 2014 | 200 | 2014 |
| Ex vivo expansion of CD4+ CD25+ FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling KG Elpek, ES Yolcu, DDH Franke, C Lacelle, RH Schabowsky, H Shirwan The Journal of Immunology 179 (11), 7295-7304, 2007 | 176 | 2007 |
| Induction of tolerance using Fas ligand: a double-edged immunomodulator N Askenasy, ES Yolcu, I Yaniv, H Shirwan Blood 105 (4), 1396-1404, 2005 | 162 | 2005 |
| Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance DM Headen, KB Woodward, MM Coronel, P Shrestha, JD Weaver, ... Nature materials 17 (8), 732-739, 2018 | 160 | 2018 |
| CD4+ CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model KG Elpek, C Lacelle, NP Singh, ES Yolcu, H Shirwan The Journal of Immunology 178 (11), 6840-6848, 2007 | 149 | 2007 |
| Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants JR Leventhal, MJ Elliott, ES Yolcu, LD Bozulic, DJ Tollerud, JM Mathew, ... Transplantation 99 (2), 288-298, 2015 | 144 | 2015 |
| Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection ES Yolcu, N Askenasy, NP Singh, SEL Cherradi, H Shirwan Immunity 17 (6), 795-808, 2002 | 124 | 2002 |
| Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors RK Sharma, KG Elpek, ES Yolcu, RH Schabowsky, H Zhao, ... Cancer research 69 (10), 4319-4326, 2009 | 102 | 2009 |
| Pancreatic islets under attack: cellular and molecular effectors M Pearl-Yafe, A Kaminitz, ES Yolcu, I Yaniv, J Stein, N Askenasy Current pharmaceutical design 13 (7), 749-760, 2007 | 99 | 2007 |
| Rapid on-demand extracellular vesicle augmentation with versatile oligonucleotide tethers SS Yerneni, S Lathwal, P Shrestha, H Shirwan, K Matyjaszewski, L Weiss, ... ACS nano 13 (9), 10555-10565, 2019 | 92 | 2019 |
| Stem cells as tools in regenerative therapy for retinal degeneration V Enzmann, E Yolcu, HJ Kaplan, ST Ildstad Archives of ophthalmology 127 (4), 563-571, 2009 | 92 | 2009 |
| Apoptosis as a mechanism of T‐regulatory cell homeostasis and suppression ES Yolcu, S Ash, A Kaminitz, Y Sagiv, N Askenasy, S Yarkoni Immunology and cell biology 86 (8), 650-658, 2008 | 90 | 2008 |
| Targeting CD4+ CD25+ FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. RH Schabowsky, S Madireddi, R Sharma, ES Yolcu, H Shirwan Current Opinion in Investigational Drugs (London, England: 2000) 8 (12 …, 2007 | 81 | 2007 |
| Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice ES Yolcu, H Zhao, L Bandura-Morgan, C Lacelle, KB Woodward, ... The Journal of Immunology 187 (11), 5901-5909, 2011 | 79 | 2011 |
| A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity NP Singh, ES Yolcu, DD Taylor, C Gercel-Taylor, DS Metzinger, ... Cancer research 63 (14), 4067-4073, 2003 | 73 | 2003 |
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines RK Sharma, RH Schabowsky, AK Srivastava, KG Elpek, S Madireddi, ... Cancer research 70 (10), 3945-3954, 2010 | 67 | 2010 |
| A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity RH Schabowsky, KG Elpek, S Madireddi, RK Sharma, ES Yolcu, ... Vaccine 28 (2), 512-522, 2009 | 67 | 2009 |
| Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection N Askenasy, ES Yolcu, Z Wang, H Shirwan Circulation 107 (11), 1525-1531, 2003 | 66 | 2003 |
| Immunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival MM Coronel, KE Martin, MD Hunckler, G Barber, EB O’Neill, JD Medina, ... Science Advances 6 (35), eaba5573, 2020 | 64 | 2020 |
| SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ S Madireddi, RH Schabowsky, AK Srivastava, RK Sharma, ES Yolcu, ... Public Library of Science 7 (8), e42459, 2012 | 58 | 2012 |
Haval ShirwanUniversity of Missouri, Columbia在 health.missouri.edu 的电子邮件经过验证
